These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 39125777)

  • 21. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions.
    Lupo KB; Moon JI; Chambers AM; Matosevic S
    Cytotherapy; 2021 Oct; 23(10):939-952. PubMed ID: 34272175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
    Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
    Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D.
    Gröschel C; Hübscher D; Nolte J; Monecke S; Sasse A; Elsner L; Paulus W; Trenkwalder C; Polić B; Mansouri A; Guan K; Dressel R
    Front Immunol; 2017; 8():870. PubMed ID: 28890717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
    Goldenson BH; Hor P; Kaufman DS
    Front Immunol; 2022; 13():841107. PubMed ID: 35185932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells.
    Lehmann D; Spanholtz J; Osl M; Tordoir M; Lipnik K; Bilban M; Schlechta B; Dolstra H; Hofer E
    Stem Cells Dev; 2012 Nov; 21(16):2926-38. PubMed ID: 22571679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
    Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
    Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.
    Ni Z; Knorr DA; Bendzick L; Allred J; Kaufman DS
    Stem Cells; 2014 Apr; 32(4):1021-31. PubMed ID: 24307574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An improved approach to generate IL-15
    Chen AP; Gao P; Lin L; Ashok P; He H; Ma C; Zou DL; Allain V; Boyne A; Juillerat A; Duchateau P; Rath A; Teper D; Arulanandam A; Chang HM; Eyquem J; Li W
    Cell Rep Methods; 2024 Sep; 4(9):100857. PubMed ID: 39260365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms.
    Ni Z; Knorr DA; Clouser CL; Hexum MK; Southern P; Mansky LM; Park IH; Kaufman DS
    J Virol; 2011 Jan; 85(1):43-50. PubMed ID: 20962093
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pluripotent Stem Cell Heterogeneity.
    Hayashi Y; Ohnuma K; Furue MK
    Adv Exp Med Biol; 2019; 1123():71-94. PubMed ID: 31016596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.
    Bogomiakova ME; Sekretova EK; Anufrieva KS; Khabarova PO; Kazakova AN; Bobrovsky PA; Grigoryeva TV; Eremeev AV; Lebedeva OS; Bogomazova AN; Lagarkova MA
    Stem Cell Res Ther; 2023 Apr; 14(1):77. PubMed ID: 37038186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.
    Lu SJ; Feng Q
    Stem Cells Transl Med; 2021 Nov; 10 Suppl 2(Suppl 2):S10-S17. PubMed ID: 34724715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
    Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
    Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs).
    Bock AM; Knorr D; Kaufman DS
    J Vis Exp; 2013 Apr; (74):e50337. PubMed ID: 23644738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15.
    McCullar V; Oostendorp R; Panoskaltsis-Mortari A; Yun G; Lutz CT; Wagner JE; Miller JS
    Exp Hematol; 2008 May; 36(5):598-608. PubMed ID: 18295962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity.
    Suzuki D; Flahou C; Yoshikawa N; Stirblyte I; Hayashi Y; Sawaguchi A; Akasaka M; Nakamura S; Higashi N; Xu H; Matsumoto T; Fujio K; Manz MG; Hotta A; Takizawa H; Eto K; Sugimoto N
    Stem Cell Reports; 2020 Jan; 14(1):49-59. PubMed ID: 31883921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Differentiation of pluripotent stem cells into male germ cells: An update].
    Wang SY; Cui YG; Qin LJ
    Zhonghua Nan Ke Xue; 2017 May; 23(5):468-472. PubMed ID: 29717842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.